Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Accumulated Expenses (2022 - 2025)

Atara Biotherapeutics' Accumulated Expenses history spans 4 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 80.71% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 80.71%, while the annual FY2025 figure was $1.3 million, 80.71% down from the prior year.
  • Accumulated Expenses reached $1.3 million in Q4 2025 per ATRA's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $19.0 million in Q4 2023 to a low of $349000.0 in Q1 2023.
  • Average Accumulated Expenses over 4 years is $8.4 million, with a median of $7.4 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: plummeted 97.87% in 2023, then soared 1535.24% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $7.4 million in 2022, then surged by 155.64% to $19.0 million in 2023, then plummeted by 65.33% to $6.6 million in 2024, then tumbled by 80.71% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Accumulated Expenses are $1.3 million (Q4 2025), $2.6 million (Q3 2025), and $4.8 million (Q2 2025).